TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20049753

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg daily
Number of subjects: 146
Study: 16773037

Group type: EXPERIMENTAL
Intervention: Sustained-release fampridine 25 mg b.i.d. (Group I)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sustained-release fampridine 40 mg b.i.d. (Group II)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 91
Study: 15788340

Group type: EXPERIMENTAL
Intervention: Triggered electrical stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-triggered electrical stimulation
Number of subjects: 22
Study: 12236050

Group type: EXPERIMENTAL
Intervention: Vaginal capsule containing 200 mg progesterone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vaginal gel containing 90 mg progesterone
Number of subjects: 24
Study: 9822445

Group type: EXPERIMENTAL
Intervention: Intermediate NaCl diet (120 mmol/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High NaCl diet (220 mmol/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low NaCl diet (20 mmol/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral glucose load during intermediate NaCl diet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral glucose load after each diet
Number of subjects: 39
Study: 8126986

Group type: EXPERIMENTAL
Intervention: PZA (2S (E) HRZ/EHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2912427

Group type: EXPERIMENTAL
Intervention: Combined drug therapy with lovastatin and colestipol
Number of subjects: 10
Study: 1098542

Group type: EXPERIMENTAL
Intervention: Classical cholera vaccine with yellow fever vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified fraction vaccine with yellow fever vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical cholera vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified fraction vaccine
Number of subjects: 0
Study: 7031741

Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study: 31332988

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sprint training
Number of subjects: 28
Study: 28327122

Group type: EXPERIMENTAL
Intervention: Midodrine (20 mg) three times a day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 120
Study: 27885221

Group type: EXPERIMENTAL
Intervention: Trial Gel B
Number of subjects: 0
Study: 24733645

Group type: EXPERIMENTAL
Intervention: 100% portion size
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 150% portion size
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 200% portion size
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight status (normal-weight vs obese)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Portion size condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: RRVF status
Number of subjects: 50
Study: 22995879

Group type: EXPERIMENTAL
Intervention: Early invasive strategy with contemporary antithrombin regimens (bivalirudin or heparin plus glycoprotein IIb/IIIa inhibitor)
Number of subjects: 2475

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 2475
Study: 19090505

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) and Kava
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18093307

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya and related practices (SK&P) - practiced daily for six weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Relaxation in an armchair (control group)
Number of subjects: 103
Study: 15102872

Group type: EXPERIMENTAL
Intervention: LE 0.1% (400 microg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LE 0.2% (800 microg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FP 0.05% (200 microg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11704889

Group type: EXPERIMENTAL
Intervention: HHV‐6 presence in patients with multiple sclerosis
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: HHV‐6 viremia in patients with multiple sclerosis
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: HHV‐7 reactivation in patients with demyelinating diseases of the peripheral nervous system
Number of subjects: 113
Study: 11990191

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 7982184

Group type: EXPERIMENTAL
Intervention: Controlled release metoclopramide (CRM) 40 mg every 12 hours for 3 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Immediate release metoclopramide (IRM) 20 mg every 6 hours for 3 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Controlled release metoclopramide (CRM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Immediate release metoclopramide (IRM)
Number of subjects: 34
Study: 2661843

Group type: EXPERIMENTAL
Intervention: 1.8% hypertonic saline (HS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 20
Study: 1064215

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine presoaked lens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% pilocarpine presoaked lens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8% pilocarpine presoaked lens
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% pilocarpine intensive drops
Number of subjects: 0
Study: 31104034

Group type: EXPERIMENTAL
Intervention: Smartphone-based visual feedback trunk control training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 24
Study: 30372781

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (Group 2)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bupivacaine with spinal narcotic (Group 1)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bupivacaine with spinal without narcotic (Group 3)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nausea or vomiting incidence in Group 1
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Nausea or vomiting incidence in Group 2
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nausea or vomiting incidence in Group 3
Number of subjects: 195

Group type: COMPARATOR
Intervention: Pruritus incidence in Group 1
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Pruritus incidence in Group 2
Number of subjects: 195

Group type: COMPARATOR
Intervention: Pruritus incidence in Group 3
Number of subjects: 195
Study: 27834574

Group type: EXPERIMENTAL
Intervention: Participation in SALSA (8-week randomized, crossover pilot study)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latin dance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Changes in psychosocial factors
Number of subjects: 50
Study: 25545629

Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: rasagiline 2 mg/day
Number of subjects: 1150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1150
Study: 23642947

Group type: EXPERIMENTAL
Intervention: 600 mg of Lf/IgF daily for 90 days
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 20605427

Group type: EXPERIMENTAL
Intervention: Pudding with 10 g oat bran DF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pudding with no added fibre
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pudding with 10 g wheat bran DF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pudding with 5 g wheat bran DF + 5 g oat bran DF
Number of subjects: 20
Study: 19424052

Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens with CNS penetration effectiveness (CPE) rank of at least 2
Number of subjects: 101

Group type: COMPARATOR
Intervention: Antiretroviral regimens with CPE rank less than 2
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens with CPE rank of at least 2 or more antiretrovirals
Number of subjects: 101

Group type: COMPARATOR
Intervention: Antiretroviral regimens with poorer CNS penetration
Number of subjects: 101
Study: 17467869

Group type: EXPERIMENTAL
Intervention: MCQ test
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CASTest
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined ALS score (one MCQ and one CASTest)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pass/fail decisions
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Generalizability theory
Number of subjects: 33
Study: 14572824

Group type: EXPERIMENTAL
Intervention: Customized Victim Impact Panel (VIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Victim Impact Panel (VIP)
Number of subjects: 0
Study: 11265104

Group type: EXPERIMENTAL
Intervention: Telephone communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fax communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-mail communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videoconferencing communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face meetings
Number of subjects: 0
Study: 8835070

Group type: EXPERIMENTAL
Intervention: 1 month replacement schedule
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 3 month replacement schedule
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-replacement (control) group
Number of subjects: 119
Study: 1572248

Group type: EXPERIMENTAL
Intervention: Captopril (2.5 or 5.0 mg slow intravenous bolus followed by continuous infusion of 1.5‐2.0 mg/h for 48 hours)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (same mode of administration as captopril)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3894127

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 0
Study: 30484733

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 27645694

Group type: EXPERIMENTAL
Intervention: High SUV1 (≥6) in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low SUV1 (<6) in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High SUV1 (≥6) in OS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low SUV1 (<6) in OS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low ALP level
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High ALP level
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low LDH level
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High LDH level
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High SUV1 in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low SUV1 in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High SUV1 in OS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low SUV1 in OS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High SUV2 in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low SUV2 in EWS patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Good metabolic response (SUV reduction of ≥55%)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Poor metabolic response
Number of subjects: 77
Study: 25435403

Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery (RIRS)
Number of subjects: 55
Study: 23294997

Group type: EXPERIMENTAL
Intervention: Known diabetes mellitus (DM)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥6.5%
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥5.7%
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Total cardiac events
Number of subjects: 320
Study: 21982313

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-defibrillator (CRT-D)
Number of subjects: 0
Study: 18507661

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin plus 1 mg glucagon
Number of subjects: 6

Group type: COMPARATOR
Intervention: 100 mg indomethacin alone (placebo)
Number of subjects: 6
Study: 16412642

Group type: EXPERIMENTAL
Intervention: Simulated slips using a custom slipping platform
Number of subjects: 22

Group type: COMPARATOR
Intervention: Actual slips induced with artificial ice
Number of subjects: 22
Study: 14642039

Group type: EXPERIMENTAL
Intervention: End-hole + sidehole catheters
Number of subjects: 22
Study: 10348155

Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Patients with epilepsy using phenytoin
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Patients with epilepsy with family fracture history
Number of subjects: 345

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 345
Study: 7561530

Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy with rifampicin (isoniazid, pyrazinamide, ethambutol, and rifampicin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti-TB chemotherapy without rifampicin (isoniazid, pyrazinamide, and ethambutol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy with rifampicin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti-TB chemotherapy without rifampicin
Number of subjects: 80
Study: 1766577

Group type: EXPERIMENTAL
Intervention: 300 mg of reduced GSH for 30 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mg of vitamin K for 30 days
Number of subjects: 80
Study: 7184670

Group type: EXPERIMENTAL
Intervention: Chlorpropamide tablet (250 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorpropamide suspension
Number of subjects: 18
Study: 29397638

Group type: EXPERIMENTAL
Intervention: OTSC® Proctology
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fistulectomy with primary sphincter reconstruction
Number of subjects: 30
Study: 28609641

Group type: EXPERIMENTAL
Intervention: Flexibility training (3×/week; 30 min/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Single bout of intense eccentric exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 25
Study: 25197738

Group type: EXPERIMENTAL
Intervention: Flossing followed by brushing (FB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Brushing followed by flossing (BF)
Number of subjects: 35
Study: 24704427

Group type: EXPERIMENTAL
Intervention: Parent-directed prenatal education teaching module about vaccination pain management (20-30 minute interactive presentation)
Number of subjects: 197

Group type: COMPARATOR
Intervention: General vaccination information (control group)
Number of subjects: 197
Study: 22409394

Group type: EXPERIMENTAL
Intervention: self‐ligating brackets
Number of subjects: 19

Group type: COMPARATOR
Intervention: conventional preadjusted brackets
Number of subjects: 19
Study: 19678780

Group type: EXPERIMENTAL
Intervention: C. domestica extracts 2 g per day for 6 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg per day for 6 weeks
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: C. domestica extracts
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 107
Study: 17181395

Group type: COMPARATOR
Intervention: Low volumetric total (D tot) and trabecular (D trab) BMDs, BV/TV, cortical thickness (Cort Th), trabecular number (TbN), trabecular thickness (TbTh), trabecular separation (TbSp), and distribution of trabecular separation (TbSpSd) at the distal radius
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Volumetric total and trabecular densities
Number of subjects: 101

Group type: COMPARATOR
Intervention: D trab, TbN, TbSp, and TbSpSd at the distal radius
Number of subjects: 101

Group type: COMPARATOR
Intervention: D tot, D trab, Cort Th, and TbTh at the distal tibia
Number of subjects: 101
Study: 15895286

Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg/day p.o. for 3 months
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 12572869

Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) 20-30 g daily for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline anti-inflammatory therapy for 4 weeks
Number of subjects: 18
Study: 9419167

Group type: EXPERIMENTAL
Intervention: Cell-free HIV‐1 in breast milk
Number of subjects: 75
Study: 9734472

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) at doses of 10(-10) to 10(-5) mol/L
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 17-octadecynoic acid (17-ODYA) at 10(-5) mol/L (P450 inhibitor)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) at 10(-5) mol/L (cyclooxygenase inhibitor)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: N omega-nitro-L-arginine methyl ester (L-NAME) at 10(-4) mol/L (NO synthase inhibitor)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Miconazole at 10(-5) mol/L (P450 inhibitor)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 40 mmol/L KCl
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Charybdotoxin at 10(-8) mol/L (large-conductance Ca2+-activated K+ channel blocker)
Number of subjects: 70
Study: 1894852

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite-and-swallow) after calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nifedipine (10 mg bite-and-swallow) after placebo infusion (5% dextrose in water)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo infusion (5% dextrose in water)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite-and-swallow) after calcium infusion
Number of subjects: 17
Study: 7051825

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31996108

Group type: EXPERIMENTAL
Intervention: New model of diabetes care introduced in 2008, which included continual monitoring, analysis, and adjustment of initiatives taken.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New model of diabetes care
Number of subjects: 0
Study: 30714984

Group type: EXPERIMENTAL
Intervention: Corticosteroids (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT) (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of corticosteroids and vestibular rehabilitation (n = 20)
Number of subjects: 60
Study: 26449210

Group type: EXPERIMENTAL
Intervention: Active Australia Survey screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-item screening tool
Number of subjects: 0
Study: 24427649

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg IV at induction of anesthesia)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21635675

Group type: COMPARATOR
Intervention: 25 mg prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg prednisone
Number of subjects: 0
Study: 17429559

Group type: EXPERIMENTAL
Intervention: Anal purse-string suture (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No anal purse-string suture (group 2)
Number of subjects: 40
Study: 16421063

Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (waiting list, n = 9)
Number of subjects: 18
Study: 14605050

Group type: EXPERIMENTAL
Intervention: Linezolid, 600 mg, q12h for 7 to 21 days
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Vancomycin, 1 g, q12h for 7 to 21 days
Number of subjects: 1019
Study: 11482708

Group type: EXPERIMENTAL
Intervention: Resting tricuspid regurgitation velocity (TRV) and right ventricular outflow tract velocity curve (RVOTvc) indices
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy asymptomatic volunteers
Number of subjects: 52
Study: 8632551

Group type: EXPERIMENTAL
Intervention: Vacuum therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Self-injection
Number of subjects: 33
Study: 1843544

Group type: EXPERIMENTAL
Intervention: Professional toothbrushing with dentifrice
Number of subjects: 53

Group type: COMPARATOR
Intervention: Professional toothbrushing with water
Number of subjects: 53
Study: 6084461

Group type: EXPERIMENTAL
Intervention: Iron prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31286387

Group type: EXPERIMENTAL
Intervention: Supervised 18-week high-intensity exercise program
Number of subjects: 109
Study: 30312159

Group type: EXPERIMENTAL
Intervention: Manualized Swedish massage therapy (SMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light touch (LT)
Number of subjects: 0
Study: 26874330

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketanserin (40mg orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salvinorin-A (1mg vaporized)
Number of subjects: 24
Study: 23884048

Group type: EXPERIMENTAL
Intervention: GMS1 (autocorrecting device)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GMS2 (noncorrecting device)
Number of subjects: 12
Study: 22196125

Group type: EXPERIMENTAL
Intervention: Early aquatic therapy (after 6 days)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Late aquatic therapy (after 14 days)
Number of subjects: 465
Study: 21048810

Group type: EXPERIMENTAL
Intervention: Silymarin and selenium (SM-Se) combination (570 mg of silymarin and 240 µg of selenium as selenomethionine)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 16955461

Group type: EXPERIMENTAL
Intervention: HCV antibody detection immunoassay
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative polymerase chain reaction assay
Number of subjects: 100
Study: 15908660

Group type: EXPERIMENTAL
Intervention: FU/LV/BV
Number of subjects: 923

Group type: COMPARATOR
Intervention: IFL/placebo
Number of subjects: 923